InceptionR’s Xenon Pharmaceuticals XENE Stock Holding History

InceptionR’s Portfolio XENE Stock Details XENE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-6,322	Closed	-$254K	–	911
2025 Q3	$254K	Buy	+6,322	New	+$223K	0.06%	517

Other funds holding XENE

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

DCM

Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return

Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

PCH

Polar Capital Holdings London, United Kingdom $42.4B AUM 181.11% 1-Year Est. Return

Braidwell Stamford, Connecticut $2.7B AUM 88.53% 1-Year Est. Return

Commodore Capital New York $1.68B AUM 375.52% 1-Year Est. Return

InceptionR's XENE Position: Q4 2025 in Review

InceptionR sold out of Xenon Pharmaceuticals (XENE) in Q4 2025, closing a stake of 6,322 shares — an estimated $254K sold.

InceptionR first reported a position in XENE in Q3 2025 and held it in 1 quarter. The position peaked at $254K in Q3 2025. 245 funds tracked by Wall St. Rank hold XENE as of Q4 2025.

InceptionR reported no remaining Xenon Pharmaceuticals position as of Q4 2025 after selling out during the quarter.
InceptionR sold 6,322 Xenon Pharmaceuticals shares in Q4 2025, an estimated $254K.
InceptionR first reported a position in Xenon Pharmaceuticals in Q3 2025 and held it in 1 quarter.
InceptionR's Xenon Pharmaceuticals position peaked at $254K in Q3 2025.
245 funds tracked by Wall St. Rank held Xenon Pharmaceuticals as of Q4 2025.

Based on InceptionR's 13F filing for Q4 2025, filed 11 Feb 2026.